NVO
Novo Nordisk A/S
NVO has the edge over OPK overall, supported by stronger fundamentals and stronger modeled upside.
OPK
OPKO Health, Inc.
OPK trails on the overall score without a compensating advantage in the available component scores.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OPK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OPK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OPK PE Valuation
OPK has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over OPK on the outlook, with more favorable revenue expectations.
OPK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect OPK's revenue and profitability to decline, with its earnings holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over OPK on earnings quality, reporting a profit while its opponent remains loss making.
OPK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.06 |
| Q2 2026 | -$0.09 | +$0.16 |
| Q1 2026 | -$0.27 | -$0.20 |
| Q4 2025 | -$0.30 | -$0.21 |
| Q3 2025 | -$0.25 | -$0.06 |
| Q2 2025 | -$0.25 | +$0.08 |
| Q1 2025 | -$0.07 | +$0.28 |
| Q4 2024 | -$0.09 | +$0.16 |
OPK is still losing money, but far less than before: $0.19 per share over the past year, against $0.53 at its worst in late 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over OPK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over OPK on profitability, with a higher operating margin.
OPK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $65.4M | -57% |
| Q2 2026 | $163.6M | +4.3% |
| Q1 2026 | $124.2M | -17% |
| Q4 2025 | $148.5M | -19% |
| Q3 2025 | $151.7M | -13% |
| Q2 2025 | $156.8M | -14% |
| Q1 2025 | $150M | -14% |
| Q4 2024 | $183.6M | +1% |
OPK's revenue has slid since its 2021 peak: $65M last quarter, down 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -48% | -80 points |
| Q2 2026 | -4.3% | +34 points |
| Q1 2026 | -41% | +3.7 points |
| Q4 2025 | -26% | -7.8 points |
| Q3 2025 | 32% | +24 points |
| Q2 2025 | -38% | -4.4 points |
| Q1 2025 | -45% | -3.6 points |
| Q4 2024 | -18% | +20 points |
OPK's operating margin was −48% last quarter, down 80 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over OPK on cash generation, producing positive trailing cash flow while its opponent burns cash.
OPK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.1M | -$1.3M |
| Q2 2026 | -$46.5M | +$40.2M |
| Q1 2026 | -$21.1M | +$16.6M |
| Q2 2025 | -$86.7M | -$53.1M |
| Q1 2025 | -$37.7M | +$2.3M |
| Q2 2024 | -$33.7M | -$27.3M |
| Q1 2024 | -$40M | -$14.3M |
| Q4 2023 | -$41.3M | -$3.4M |
OPK has burned cash in most quarters: −$135M over the past year, against −$196M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
OPK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -8.8M shares |
| 1 year | -4.3% | -33.4M shares |
| 3 years | -0.7% | -5M shares |
| 5 years | +15% | +94.6M shares |
| Available history | +25% | +151M shares |
OPK has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10.6M |
| Q2 2026 | $13M |
| Q1 2026 | $4.8M |
| Q4 2025 | $13.5M |
| Q3 2025 | $15.3M |
| Q2 2025 | $18.3M |
| Q1 2025 | — |
| Q4 2024 | $16.5M |
OPK spent $42M buying back its own shares over the past year, down 16% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
OPK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -7.2x | Net Cash |
| Q4 2021 | 0.7x | Very low |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.3x | Net Cash |
| Q1 2021 | -0.4x | Net Cash |
| Q4 2020 | 1.3x | Healthy |
OPK has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
OPK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.9 | Neutral |
| Stochastic | 74.7 | Neutral |
OPK's weekly RSI is 59 (neutral) and its Stochastic is 75 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OPK PE vs Healthcare Sector
| Metric | OPK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
OPK has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
OPK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.60 | 4.4% above |
| 20 week MA | $1.50 | 11% above |
| 50 week MA | $1.36 | 23% above |
| 100 week MA | $1.40 | 19% above |
| 200 week MA | $1.42 | 18% above |
OPK has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
OPK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.50 | $4.23 | +182% |
| 2021 | $4.23 | $4.77 | +13% |
| 2022 | $4.77 | $1.14 | -76% |
| 2023 | $1.14 | $1.51 | +32% |
| 2024 | $1.51 | $1.48 | -2% |
| 2025 | $1.48 | $1.29 | -13% |
| 2026 YTD | $1.29 | $1.67 | +29% |
OPK has the edge over NVO on returns for 2026, with the stronger performance.